Study sheds light on treating cancer
Using light to target and kill cancer cells alternatively without surgery
A new study, affiliated with UNIST has presented a natural, alternative, and holistic cancer treatment that uses light to selectively wipe out cancerous cells without harming surrounding tissue. With further research, this novel method might eventually be used to treat tumors in humans.
This study was jointly conducted by Prof. Tae-Hyuk Kwon (School Natural Science), Prof. Mi Hee Lim (School of Natural Science), and Prof. Hyun-Woo Rhee (School of Natural Science), and eight other researchers at UNIST.
In the study, the team developed photodynamic therapy (PDT) agent composed of Ir(III) complexes for cancer cells via a molecular design strategy for efficient ROS generation that accounted for appropriate energy levels and high emission quantum yields.
The team expects that their Ir(III) complexes could be used for additive-free photo-cross-linking in other fields beyound PDT.
Original publication
Jung Seung Nam, Myeong-Gyun Kang, Juhye Kang, Sun-Young Park, Shin Jung C. Lee, Hyun-Tak Kim, Jeong Kon Seo, Oh-Hoon Kwon, Mi Hee Lim, Hyun-Woo Rhee, and Tae-Hyuk Kwon; "Endoplasmic Reticulum-Localized Iridium(III) Complexes as Efficient Photodynamic Therapy Agents via Protein Modifications"; JACS; 2016
Original publication
Jung Seung Nam, Myeong-Gyun Kang, Juhye Kang, Sun-Young Park, Shin Jung C. Lee, Hyun-Tak Kim, Jeong Kon Seo, Oh-Hoon Kwon, Mi Hee Lim, Hyun-Woo Rhee, and Tae-Hyuk Kwon; "Endoplasmic Reticulum-Localized Iridium(III) Complexes as Efficient Photodynamic Therapy Agents via Protein Modifications"; JACS; 2016
Topics
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

First structural map of cystic fibrosis protein sheds light on how mutations cause disease
Scientists identify gene that predicts post-surgical survival from brain metastasis of breast cancer patients

Silver nanoparticles take spectroscopy to new dimension - A new way of organizing nanostructures has boosted Raman signals by a hundred thousand times to better identify and characterize different molecules

Software revolution for clinical trials - Health Tech Start-up Carelane Raises €800,000 in Pre-Seed Funding

Multitasking with perfection: Nerve cell works like 1400 individual cells - Amacrine cell in the fruit fly visual system consists of electrically isolated subunits

Starvation causes cell remodelling - Researchers discover previously unknown mechanism

Pharmaceutical research: when active substance and target protein “embrace” each other

4Tissue raises €2m to advance groundbreaking breast tissue replacement technology - A revolutionary approach
